AU2004238500B2 - Azaindole-derivatives as factor Xa inhibitors - Google Patents

Azaindole-derivatives as factor Xa inhibitors Download PDF

Info

Publication number
AU2004238500B2
AU2004238500B2 AU2004238500A AU2004238500A AU2004238500B2 AU 2004238500 B2 AU2004238500 B2 AU 2004238500B2 AU 2004238500 A AU2004238500 A AU 2004238500A AU 2004238500 A AU2004238500 A AU 2004238500A AU 2004238500 B2 AU2004238500 B2 AU 2004238500B2
Authority
AU
Australia
Prior art keywords
alkyl
pyridine
unsubstituted
pyrrolo
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2004238500A
Other languages
English (en)
Other versions
AU2004238500A1 (en
Inventor
Hans Matter
Marc Nazare
Kurt Ritter
Matthias Urmann
Volkmar Wehner
David William Will
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Publication of AU2004238500A1 publication Critical patent/AU2004238500A1/en
Application granted granted Critical
Publication of AU2004238500B2 publication Critical patent/AU2004238500B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2004238500A 2003-05-19 2004-05-05 Azaindole-derivatives as factor Xa inhibitors Expired - Fee Related AU2004238500B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03011304.7 2003-05-19
EP03011304A EP1479680A1 (en) 2003-05-19 2003-05-19 Azaindole derivatives as Factor Xa inhibitors
PCT/EP2004/004754 WO2004101563A1 (en) 2003-05-19 2004-05-05 AZAINDOLE-DERIVATIVES AS FACTOR Xa INHIBITORS

Publications (2)

Publication Number Publication Date
AU2004238500A1 AU2004238500A1 (en) 2004-11-25
AU2004238500B2 true AU2004238500B2 (en) 2010-07-22

Family

ID=33040951

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004238500A Expired - Fee Related AU2004238500B2 (en) 2003-05-19 2004-05-05 Azaindole-derivatives as factor Xa inhibitors

Country Status (24)

Country Link
EP (2) EP1479680A1 (cg-RX-API-DMAC7.html)
JP (1) JP4733642B2 (cg-RX-API-DMAC7.html)
KR (1) KR20060012636A (cg-RX-API-DMAC7.html)
CN (1) CN100347172C (cg-RX-API-DMAC7.html)
AR (1) AR045682A1 (cg-RX-API-DMAC7.html)
AU (1) AU2004238500B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0410429A (cg-RX-API-DMAC7.html)
CA (1) CA2526084A1 (cg-RX-API-DMAC7.html)
CL (1) CL2004001079A1 (cg-RX-API-DMAC7.html)
CR (1) CR8088A (cg-RX-API-DMAC7.html)
EC (1) ECSP056179A (cg-RX-API-DMAC7.html)
MA (1) MA27799A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA05012156A (cg-RX-API-DMAC7.html)
NO (1) NO20055911L (cg-RX-API-DMAC7.html)
NZ (1) NZ543669A (cg-RX-API-DMAC7.html)
OA (1) OA13169A (cg-RX-API-DMAC7.html)
PE (1) PE20050554A1 (cg-RX-API-DMAC7.html)
RS (1) RS20050857A (cg-RX-API-DMAC7.html)
RU (1) RU2330853C2 (cg-RX-API-DMAC7.html)
TN (1) TNSN05296A1 (cg-RX-API-DMAC7.html)
TW (1) TW200510411A (cg-RX-API-DMAC7.html)
UA (1) UA86767C2 (cg-RX-API-DMAC7.html)
WO (1) WO2004101563A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200508150B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7622466B2 (en) * 2005-11-18 2009-11-24 Hoffman-La Roche Inc. Azaindole-2-carboxamide derivatives
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
US9345247B2 (en) 2012-08-17 2016-05-24 Bayer Cropscience Ag Azaindole carboxylic acid amides and azaindole thiocarboxylic acid amides for use as insecticides and acaricides
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
CN111834531B (zh) * 2019-04-15 2022-04-19 天津大学 一种有机半导体材料、制备方法及应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1241472B (it) 1990-07-06 1994-01-17 Olivier Linda Dispositivo elettromeccanico per la cattura continua in particolare di topi e ratti.
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
ZA953361B (en) 1994-04-26 1996-01-12 Selectide Corp Factor Xa inhibitors
ZA964008B (en) * 1995-06-02 1997-07-11 Akzo Nobel Nv Imidazo[1,5a]pyridine derived serine protease inhibitors
NZ503809A (en) * 1997-12-19 2002-04-26 Schering Ag Ortho-anthranilamide derivatives as anti-coagulants
BR9814340B1 (pt) * 1997-12-24 2010-07-13 compostos derivados de indol, processo para a preparação dos mesmo e composição farmacêutica.
EP0987274A1 (en) 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
JP4241970B2 (ja) * 1998-10-30 2009-03-18 中外製薬株式会社 アミド結合を有するインドール誘導体、及びモノ又はジアザインドール誘導体
CZ2002961A3 (cs) * 1999-09-17 2002-08-14 Millennium Pharmaceuticals, Inc. Benzamidy a příbuzné sloučeniny pro inhibici faktoru Xa
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
JP2001294572A (ja) * 2000-02-09 2001-10-23 Dai Ichi Seiyaku Co Ltd 新規スルホニル誘導体
US6436965B1 (en) * 2000-03-02 2002-08-20 Merck Frosst Canada & Co. PDE IV inhibiting amides, compositions and methods of treatment
AU2001273040A1 (en) * 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
WO2002070523A1 (en) * 2001-03-07 2002-09-12 Pfizer Products Inc. Modulators of chemokine receptor activity
AU2002303264A1 (en) * 2001-04-09 2002-10-21 Bristol-Myers Squibb Company Fused heterocyclic inhibitors of factor xa
EP1314733A1 (en) * 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
EA012926B1 (ru) * 2001-12-20 2010-02-26 Оси Фармасьютикалз, Инк. Пирролопиримидиновые соединения, относящиеся к a-селективным антагонистам, их синтез и применение
DE10214832A1 (de) * 2002-04-04 2003-10-16 Merck Patent Gmbh Phenylderivate 4
JP2004203791A (ja) * 2002-12-25 2004-07-22 Dai Ichi Seiyaku Co Ltd 芳香族化合物
JP2004210716A (ja) * 2002-12-27 2004-07-29 Dai Ichi Seiyaku Co Ltd ジアミド誘導体
US7135469B2 (en) * 2003-03-18 2006-11-14 Bristol Myers Squibb, Co. Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors

Also Published As

Publication number Publication date
WO2004101563A1 (en) 2004-11-25
CL2004001079A1 (es) 2005-04-08
MXPA05012156A (es) 2006-08-18
CN1791601A (zh) 2006-06-21
NO20055911L (no) 2006-02-10
JP4733642B2 (ja) 2011-07-27
EP1479680A1 (en) 2004-11-24
TNSN05296A1 (en) 2007-07-10
RU2005139557A (ru) 2007-06-27
CR8088A (es) 2006-09-22
ECSP056179A (es) 2006-08-30
EP1636226A1 (en) 2006-03-22
UA86767C2 (ru) 2009-05-25
ZA200508150B (en) 2007-02-28
RS20050857A (sr) 2007-11-15
NZ543669A (en) 2008-12-24
BRPI0410429A (pt) 2006-06-06
AR045682A1 (es) 2005-11-09
AU2004238500A1 (en) 2004-11-25
OA13169A (en) 2006-12-13
RU2330853C2 (ru) 2008-08-10
EP1636226B1 (en) 2014-10-15
CA2526084A1 (en) 2004-11-25
TW200510411A (en) 2005-03-16
JP2006528214A (ja) 2006-12-14
HK1089175A1 (zh) 2006-11-24
KR20060012636A (ko) 2006-02-08
CN100347172C (zh) 2007-11-07
PE20050554A1 (es) 2005-08-04
MA27799A1 (fr) 2006-03-01

Similar Documents

Publication Publication Date Title
AU2004238495B2 (en) New indole derivatives as factor Xa inhibitors
US20080280946A1 (en) Azaindole-Derivatives As Factor Xa Inhibitors
AU2002351918B2 (en) Indole-2-carboxamides as factor Xa inhibitors
AU2004238499A1 (en) Indazole-derivatives as factor Xa inhibitors
AU2005219507A1 (en) Pyrrole-derivatives as factor Xa inhibitors
US20050009827A1 (en) Triazole-derivatives as factor Xa inhibitors
AU2004238498B2 (en) Triazole-derivatives as factor Xa inhibitors
US7741341B2 (en) Benzimidazole-derivatives as factor Xa inhibitors
AU2004238497B2 (en) Benzimidazole-derivatives as factor Xa inhibitors
AU2003285336A1 (en) IMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
RU2330853C2 (ru) АЗАИНДОЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Xa

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee